Table 2.
The OGLA and OLGIM staging before the diagnosis of EGC in the Hp-eradicated and control groups before and after propensity-score matching.
| All patients (n = 186) |
Propensity score-matched patients (n = 124) |
|||||
|---|---|---|---|---|---|---|
| Hp-eradicated group n = 81 (%) |
Control group n = 105 (%) |
P value | Hp-eradicated group n = 62 (%) |
Control group n = 62 (%) |
P value | |
| OLGA | 0.375 | 0.346 | ||||
| I | 16 (19.8) | 15 (14.3) | 14 (22.6) | 8 (12.9) | ||
| II | 24 (29.6) | 49 (46.7) | 17 (27.4) | 34 (54.8) | ||
| III | 38 (46.9) | 39 (37.1) | 29 (46.8) | 19 (30.6) | ||
| IV | 3 (3.7) | 2 (1.9) | 2 (3.2) | 1 (1.6) | ||
| OLGA | 0.066 | 0.045 | ||||
| I-II | 40 (49.4) | 66 (62.9) | 31 (32.3) | 42 (67.7) | ||
| III-IV | 41 (50.6) | 39 (37.1) | 31 (50.0) | 20 (50.0) | ||
| OLGIM | 0.988 | 0.979 | ||||
| I | 20 (24.7) | 18 (17.1) | 18 (29.0) | 9 (14.5) | ||
| II | 24 (29.6) | 46 (43.8) | 15 (24.2) | 32 (51.6) | ||
| III | 35 (43.2) | 37 (35.2) | 27 (43.5) | 18 (29.0) | ||
| IV | 2 (2.5) | 4 (3.8) | 2 (3.2) | 3 (4.8) | ||
| OLGIM | 0.240 | 0.143 | ||||
| I-II | 44 (54.3) | 66 (62.9) | 33 (53.2) | 41 (66.1) | ||
| III-IV | 37 (45.7) | 39 (37.1) | 29 (46.8) | 21 (33.9) | ||